MCID: LYM025
MIFTS: 53

Lymphedema

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lymphedema

MalaCards integrated aliases for Lymphedema:

Name: Lymphedema 58 29 54 42 39 71

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

MESH via Orphanet 44 D008209
UMLS via Orphanet 72 C0024236
Orphanet 58 ORPHA79383
UMLS 71 C0024236

Summaries for Lymphedema

MedlinePlus : 42 Lymphedema is the name of a type of swelling. It happens when lymph builds up in your body's soft tissues. Lymph is a fluid that contains white blood cells that defend against germs. It can build up when the lymph system is damaged or blocked. It usually happens in the arms or legs. Causes of lymphedema include Infection Cancer Scar tissue from radiation therapy or surgical removal of lymph nodes Inherited conditions in which lymph nodes or vessels are absent or abnormal Treatment can help control symptoms. It includes exercise, compression devices, skin care, and massage. NIH: National Cancer Institute

MalaCards based summary : Lymphedema is related to cholestasis-lymphedema syndrome and hereditary lymphedema ia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Lymphedema is FLT4 (Fms Related Receptor Tyrosine Kinase 4), and among its related pathways/superpathways are Heart Development and Angiogenesis (CST). The drugs Tacrolimus and Bacitracin have been mentioned in the context of this disorder. Affiliated tissues include Heart, breast and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and cardiovascular system

Wikipedia : 74 Lymphedema, also known as lymphoedema and lymphatic edema, is a condition of localized swelling caused... more...

Related Diseases for Lymphedema

Diseases in the Lymphedema family:

Hereditary Lymphedema Hereditary Lymphedema Ic
Hereditary Lymphedema Id Hereditary Lymphedema Ia
Hereditary Lymphedema Ib Hereditary Lymphedema I
Hereditary Lymphedema Ii Congenital Lymphedema
Primary Lymphedema Celsr1-Related Late-Onset Primary Lymphedema
Gjc2-Related Late-Onset Primary Lymphedema

Diseases related to Lymphedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 584)
# Related Disease Score Top Affiliating Genes
1 cholestasis-lymphedema syndrome 33.9 SOX18 CCBE1
2 hereditary lymphedema ia 33.7 GATA2 FLT4
3 lymphatic malformation 1 33.7 VEGFC FLT4
4 hereditary lymphedema ii 33.6 SOX18 FOXC2 FLT4
5 hereditary lymphedema ic 33.6 GATA2 FLT4
6 hereditary lymphedema i 33.5 SOX18 FLT4 CCBE1
7 lymphatic malformation 5 33.4 SOX18 FOXC2
8 yellow nail syndrome 33.3 SOX18 FOXC2
9 primary lymphedema 33.0 VEGFC FOXC2 FLT4
10 congenital lymphedema 32.5 VEGFC KIF11 FOXC2 FLT4
11 hereditary lymphedema 32.5 VEGFC SOX18 FOXC2 FLT4 CCBE1
12 klippel-trenaunay-weber syndrome 31.7 SOX18 FOXC2 FLT4
13 hennekam syndrome 31.2 VEGFC SOX18 FOXC2 FLT4 CCBE1 ADAMTS3
14 lymphatic system disease 30.7 VEGFC SOX18 FOXC2 FLT4 CCBE1
15 filariasis 30.7 FOXC2 FLT4
16 lymphangitis 30.7 VEGFC FLT4
17 lymphangioma 30.2 VEGFC FLT4
18 hypotrichosis 29.6 SOX18 FOXC2 FLT4
19 gorham's disease 29.5 VEGFC FLT4
20 lymphedema-distichiasis syndrome 12.8
21 microcephaly with or without chorioretinopathy, lymphedema, or mental retardation 12.7
22 hypotrichosis-lymphedema-telangiectasia syndrome 12.7
23 hennekam lymphangiectasia-lymphedema syndrome 1 12.7
24 lymphedema, primary, with myelodysplasia 12.6
25 hennekam lymphangiectasia-lymphedema syndrome 2 12.6
26 ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema 12.6
27 choanal atresia and lymphedema 12.6
28 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 12.6
29 hennekam lymphangiectasia-lymphedema syndrome 3 12.6
30 lymphedema-hypoparathyroidism syndrome 12.5
31 lymphedema and cerebral arteriovenous anomaly 12.4
32 hereditary lymphedema id 12.4
33 lymphedema, cardiac septal defects, and characteristic facies 12.3
34 hereditary lymphedema ib 12.3
35 agenesis of the corpus callosum and congenital lymphedema 12.2
36 warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome 12.2
37 lymphatic malformation 3 12.2
38 lymphatic malformation 4 12.1
39 congenital primary lymphedema of gordon 12.1
40 congenital primary lymphedema without systemic or visceral involvement 12.0
41 late-onset primary lymphedema without systemic or visceral involvement 12.0
42 genetic primary lymphedema 12.0
43 obsolete: primary lymphedema with associated anomalies 12.0
44 primary lymphedema without systemic or visceral involvement 12.0
45 obsolete: lymphedema tarda 12.0
46 obsolete: lymphedema praecox 12.0
47 celsr1-related late-onset primary lymphedema 12.0
48 disorder with multisystemic involvement and primary lymphedema 12.0
49 primary lymphedema with systemic or visceral involvement 12.0
50 gjc2-related late-onset primary lymphedema 12.0

Graphical network of the top 20 diseases related to Lymphedema:



Diseases related to Lymphedema

Symptoms & Phenotypes for Lymphedema

UMLS symptoms related to Lymphedema:


angina pectoris, edema, chest pain, peau d'orange

GenomeRNAi Phenotypes related to Lymphedema according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.23 ADAMTS3 CCBE1 FLT4 FOXC2 GATA2 KIF11

MGI Mouse Phenotypes related to Lymphedema:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 ADAMTS3 FLT4 FOXC2 GATA2 PTPN14 SOX18
2 growth/size/body region MP:0005378 9.87 ADAMTS3 FLT4 FOXC2 GATA2 KIF11 PTPN14
3 homeostasis/metabolism MP:0005376 9.86 ADAMTS3 CCBE1 FLT4 FOXC2 GATA2 PTPN14
4 immune system MP:0005387 9.7 ADAMTS3 CCBE1 FLT4 FOXC2 PTPN14 SOX18
5 liver/biliary system MP:0005370 9.35 ADAMTS3 CCBE1 FLT4 FOXC2 GATA2
6 mortality/aging MP:0010768 9.28 ADAMTS3 CCBE1 FLT4 FOXC2 GATA2 KIF11

Drugs & Therapeutics for Lymphedema

Drugs for Lymphedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
2
Bacitracin Approved, Vet_approved Phase 2, Phase 3 1405-87-4 439542 10909430
3
Polymyxin B Approved, Vet_approved Phase 2, Phase 3 1404-26-8
4
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
5 Fibrin Tissue Adhesive Phase 3
6 Hemostatics Phase 3
7 Coagulants Phase 3
8 Polymyxins Phase 2, Phase 3
9 Calcineurin Inhibitors Phase 2, Phase 3
10 Anti-Infective Agents, Local Phase 2, Phase 3
11 Gramicidin Phase 2, Phase 3
12 Omega 3 Fatty Acid Phase 3
13 Antiparasitic Agents Phase 3
14 Antiprotozoal Agents Phase 3
15 Antimalarials Phase 3
16
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
17
Selenious acid Approved, Investigational Phase 2 7783-00-8
18
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
19
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
20
Somatostatin Approved, Investigational Phase 2 51110-01-1, 38916-34-6 53481605
21
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
22
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
23
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
24
Propranolol Approved, Investigational Phase 2 525-66-6 4946
25
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
26
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
27
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
28
Methylene blue Approved, Investigational Phase 2 61-73-4
29
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
30
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
31 Kava Approved, Investigational, Nutraceutical Phase 1, Phase 2 9000-38-8
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
33
Ubenimex Investigational Phase 2 58970-76-6
34
Horse chestnut Experimental Phase 2
35 Tocotrienol Investigational Phase 2 6829-55-6
36 Antioxidants Phase 2
37 Platelet Aggregation Inhibitors Phase 2
38 Adjuvants, Immunologic Phase 2
39 Protective Agents Phase 2
40 Pycnogenols Phase 2
41 HIV Protease Inhibitors Phase 2
42
protease inhibitors Phase 2
43 Anti-HIV Agents Phase 2
44 Endothelial Growth Factors Phase 2
45 Mitogens Phase 2
46 Antineoplastic Agents, Immunological Phase 2
47 Sodium Selenite Phase 2
48 Vitamins Phase 2
49 Tocopherols Phase 2
50 Free Radical Scavengers Phase 2

Interventional clinical trials:

(show top 50) (show all 396)
# Name Status NCT ID Phase Drugs
1 Low Level Laser Treatment and Breast Cancer Related Lymphedema Completed NCT00852930 Phase 4
2 Placebo-controlled, Case-controlled, Open Label Therapeutic Trial for Unilateral or Bilateral Lymphedema of Arm or Leg. Completed NCT02257970 Phase 4 Ketoprofen;Placebo
3 Prospective, Randomized Controlled Trial Comparing the Effect of CircAid(R) Juxta-Fit(tm) Versus Trico Bandages in the Treatment of Leg Lymphedema Completed NCT01068431 Phase 4
4 A Randomized Control Trial for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
5 Prospective, Randomized Controlled Trial Comparing the Effect of a Non-elastic Compression Device Juxta Reduction Kit (Medi ®)" Versus Elastic Class 1 Stockings (BSN Medical® in Patients Undergoing Total Knee Arthroplasty Completed NCT02375945 Phase 4
6 A Comparison of Dermal Autograft to Commercially Available Dermal Allograft in Breast Reconstruction Completed NCT01561287 Phase 4
7 Individualisation du Drainage Lymphatique Des Membres inférieurs Lors du Curage Pelvien Pour Cancer gynécologique Active, not recruiting NCT01946672 Phase 4
8 Standardization of Indocyanine Green Lymphography Protocol With Exercise for Lymphedema Assessment Enrolling by invitation NCT03584633 Phase 4 Indocyanine Green
9 Use of Pulsed Electromagnetic Fields in Reducing Arm and Shoulder Complaints in Breast Cancer Patients After Lymph Node Dissection Terminated NCT01255631 Phase 4
10 A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer Terminated NCT00534937 Phase 4
11 Randomized Trial of Pelvic and Lower Extremity Exercise in Patients Who Underwent Pelvic Lymphadenectomy With Lower Extremity Edema-related Symptoms Unknown status NCT01849224 Phase 3
12 A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome Unknown status NCT00633971 Phase 3
13 Prospective Randomized Study Comparing Mastectomy Outcomes With Versus Without the Application of Autologous Blood Products to the Surgical Site Unknown status NCT00802477 Phase 3
14 A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer Completed NCT00376597 Phase 3
15 Lymphedema Treatment of Post-surgical Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy Completed NCT02574780 Phase 2, Phase 3
16 A Phase III Clinical Trial Use of TISSEEL VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies Completed NCT00028951 Phase 3 fibrin sealant
17 DELTA - A Randomized Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer Completed NCT00201890 Phase 3
18 Individualisation of the Lymphatic Arm Drainage During Axillary Dissection for Breast Carcinomas. Completed NCT01146158 Phase 3
19 Does Scar Tissue Massage Improve Postoperative Pain and Function in Women With Breast Cancer? A Randomized Controlled Study. Completed NCT00175344 Phase 3
20 Efficacy of a Fibrin Sealant (Tissucol Duo®) for the Prevention of Lymphocele After Laparoscopic Pelvic Lymphadenectomy Due to Gynaecological Cancer: a Randomised Controlled Trial Completed NCT03914963 Phase 3
21 A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial Completed NCT01470677 Phase 3 Tachosil fibrin patch
22 Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting Recruiting NCT03776721 Phase 3
23 ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping Recruiting NCT03927027 Phase 3 Isosulfan Blue
24 Malar Bags After Lower Lid Blepharoplasty and Facelift: A Randomized Controlled Trial of the Effects of Tacrolimus Recruiting NCT03715387 Phase 2, Phase 3 Tacrolimus Topical 0.1% Topical Ointment;Polysporin Ointment
25 RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction Recruiting NCT03414970 Phase 3
26 Evaluating the Use of Enhanced Recovery Preoperative Immunonutrition and Carbohydrate Loading Strategies in Immediate Autologous and Alloplastic Breast Reconstruction Recruiting NCT03764943 Phase 3
27 Inguinal or Ilio-inguinal Lymphadenectomy for Patients With Metastatic Melanoma to Groin Lymph Nodes and no Evidence of Pelvic Disease on PET/CT Scan - A Randomised Phase III Trial (EAGLE FM) Recruiting NCT02166788 Phase 3
28 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
29 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
30 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
31 A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer Not yet recruiting NCT04073706 Phase 3
32 A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy Terminated NCT00577317 Phase 3
33 Fat Grafting Used for the Treatment of Breast Cancer Related Lymphedema in China Unknown status NCT02981485 Phase 2
34 A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer Unknown status NCT01406769 Phase 2
35 Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer Unknown status NCT02592213 Phase 2
36 Randomized Phase II Trial Of Hyperbaric Oxygen Therapy In Patients With Chronic Arm Lymphoedema After Radiotherapy For Cancer Unknown status NCT00077090 Phase 2 hyperbaric oxygen
37 Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications (Therapeutische Bewertung Von Armkompressionsstrümpfen für Lymphatische Indikationen BF09-PH-01) Unknown status NCT01318785 Phase 2
38 Treatment of Lymphedema- Application of the Kinesio Taping Unknown status NCT00155220 Phase 2
39 Axillary Reverse Mapping in Breast Cancer Unknown status NCT01038908 Phase 2
40 Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication Unknown status NCT01007604 Phase 2
41 Lymphadenectomy After Neo-Adjuvant Chemotherapy in Ovarian Neoplasm Unknown status NCT01724944 Phase 1, Phase 2
42 Treatment of Arm Lymphedema in Breast Cancer Survivors: A Double-Blind, Randomized Study of Pycnogenol vs. Placebo Completed NCT00214032 Phase 2 Pycnogenol;Placebo
43 Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA) Completed NCT02700529 Phase 2 ubenimex
44 A Single-blind, Randomized Trial of Horse Chestnut Seed Extract for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors Completed NCT00213928 Phase 2 Horse Chestnut Seed Extract
45 Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors Completed NCT00064857 Phase 2 Pycnogenol
46 Acupuncture for the Treatment of Chronic Lymphedema: A Feasibility Study Completed NCT01003951 Phase 2
47 A Phase II Study of VEGF Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer Completed NCT00827372 Phase 2 Pazopanib
48 A Randomized Phase II Placebo-controlled Double Blind Study of Using Selenium in the Treatment of Secondary Lymphedema in Breast Cancer Patients Completed NCT00188604 Phase 2 sodium selenite
49 The Effect of Combined Decongestive Therapy and Pneumatic Compression Pump on Body Image in Patients With Lymphedema Secondary to Breast Cancer Treatment Completed NCT02650297 Phase 1, Phase 2
50 Acupuncture for Chronic Lymphedema: A Randomized Wait-list Controlled Trial Completed NCT01706081 Phase 2

Search NIH Clinical Center for Lymphedema

Genetic Tests for Lymphedema

Genetic tests related to Lymphedema:

# Genetic test Affiliating Genes
1 Lymphedema 29

Anatomical Context for Lymphedema

MalaCards organs/tissues related to Lymphedema:

40
Breast, Lymph Node, Skin, Endothelial, Testes, Heart, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphedema:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Cardinal Veins Venous Endothelial Cells Affected by disease, potential therapeutic candidate

Publications for Lymphedema

Articles related to Lymphedema:

(show top 50) (show all 7349)
# Title Authors PMID Year
1
Effectiveness of Yoga Interventions in Breast Cancer-Related lymphedema: A systematic review. 61 42
31383443 2019
2
Comparison of Outcomes between Side-to-End and End-to-End Lymphovenous Anastomoses for Early-Grade Extremity Lymphedema. 61 42
31348365 2019
3
Compression in young people living with lymphoedema. 42
31348704 2019
4
A case of lymphedema-distichiasis syndrome carrying a new de novo frameshift FOXC2 mutation. 54 61
20450314 2010
5
c. 595-596 insC of FOXC2 underlies lymphedema, distichiasis, ptosis, ankyloglossia, and Robin sequence in a Thai patient. 54 61
20186799 2010
6
Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2. 54 61
20218083 2009
7
Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. 54 61
19554509 2009
8
Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2. 54 61
19394045 2009
9
Elephantiasis, elastin, and chronic wound healing: 19th century and contemporary viewpoints relevant to hypotheses concerning lymphedema, leprosy, erysipelas, and psoriasis--review and reflections. 54 61
19499764 2009
10
Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. 54 61
19302023 2009
11
T1alpha/podoplanin is essential for capillary morphogenesis in lymphatic endothelial cells. 54 61
18658274 2008
12
Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. 54 61
18041747 2008
13
[Experimental study of gene therapy with human vascular endothelial growth factor-c in lymphedema]. 54 61
18269031 2007
14
Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. 54 61
17372167 2007
15
An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. 54 61
17176124 2006
16
Update on the molecular genetics of vascular anomalies. 54 61
16379592 2005
17
The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sry-related high mobility group box gene, Sox18. 54 61
14634005 2004
18
Lymphangiogenic growth factors, receptors and therapies. 54 61
12888864 2003
19
A novel 5q35.3 subtelomeric deletion syndrome. 54 61
12900893 2003
20
Age of onset in hereditary lymphedema. 54 61
12838201 2003
21
VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. 54 61
12618526 2003
22
Preclinical models of lymphatic disease: the potential for growth factor and gene therapy. 54 61
12543717 2002
23
Insights into the molecular pathogenesis and targeted treatment of lymphedema. 54 61
12543720 2002
24
FOXC2 truncating mutation in distichiasis, lymphedema, and cleft palate. 54 61
12485195 2002
25
Molecular control of lymphangiogenesis. 54 61
12386934 2002
26
Lymphedema-distichiasis syndrome and FOXC2 gene mutation. 54 61
12383817 2002
27
Lymphangiogenic gene therapy with minimal blood vascular side effects. 54 61
12235206 2002
28
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. 54 61
12060670 2002
29
SHOX nullizygosity and haploinsufficiency in a Japanese family: implication for the development of Turner skeletal features. 54 61
11889214 2002
30
A model for gene therapy of human hereditary lymphedema. 54 61
11592985 2001
31
Truncating mutations in FOXC2 cause multiple lymphedema syndromes. 54 61
11371511 2001
32
CEST MRI quantification procedures for breast cancer treatment-related lymphedema therapy evaluation. 61
31631410 2020
33
Cancer Rehabilitation: Acute and Chronic Issues, Nerve Injury, Radiation Sequelae, Surgical and Chemo-Related, Part 1. 61
32035566 2020
34
Staging and clinical correlations of lymphoscintigraphy for unilateral gynecological cancer-related lymphedema. 61
31875981 2020
35
Impact of interscalene nerve block on lymphedema in a post-mastectomy patient undergoing shoulder surgery. 61
31437599 2020
36
Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer. 61
32031628 2020
37
An Evaluation of Safety and Patient Outcomes for Hand Surgery following Prior Breast Cancer Treatment: Establishing New Recommendations in Lymphedema. 61
31985641 2020
38
Regional Patterns of Fluid and Fat Accumulation in Patients with Lower Extremity Lymphedema Using Magnetic Resonance Angiography. 61
31985658 2020
39
Complementary low-level laser therapy for breast cancer-related lymphedema: a pilot, double-blind, randomized, placebo-controlled study. 61
31079232 2020
40
The potential use of the deep lymphatic vessels along the posterior tibial artery for treatment of lower extremity lymphedema. 61
32039496 2020
41
The Roles of Podoplanin-Positive/Podoplanin-Negative Cells from Adipose-Derived Stem Cells in Lymphatic Regeneration. 61
31985635 2020
42
Discussion: An Evaluation of Safety and Patient Outcomes for Hand Surgery following Prior Breast Cancer Treatment: Establishing New Recommendations in Lymphedema. 61
31985642 2020
43
Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review. 61
32020394 2020
44
Uncovering Lymphatic Transport Abnormalities in Patients with Primary Lipedema. 61
31546262 2020
45
Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. 61
31505689 2020
46
A curious cause of bilateral upper extremity lymphedema: 'Puffy hand syndrome'. 61
31797745 2020
47
Quality of Life and Limb: Reducing Lymphedema Risk After Breast Cancer Therapy. 61
31928634 2020
48
Indocyanine green lymphography can be falsely negative in early extremity lymphedema. 61
31727493 2020
49
Body Positional Effects on Bioimpedance Spectroscopy Measurements for Lymphedema Assessment of the Arm. 61
32027213 2020
50
Superior Clinical, Quality of Life, Functional, and Health Economic Outcomes with Pneumatic Compression Therapy for Lymphedema. 61
31629128 2020

Variations for Lymphedema

ClinVar genetic disease variations for Lymphedema:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIF11 NM_004523.4(KIF11):c.862_871del (p.Ile288fs)deletion Likely pathogenic 374219 rs1057518980 10:94373203-94373212 10:92613446-92613455
2 MET NM_001127500.3(MET):c.71G>A (p.Gly24Glu)SNV Conflicting interpretations of pathogenicity 134649 rs180985111 7:116339209-116339209 7:116699155-116699155

Expression for Lymphedema

Search GEO for disease gene expression data for Lymphedema.

Pathways for Lymphedema

Pathways related to Lymphedema according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.92 VEGFC FOXC2
2 10.75 VEGFC PTPN14 FLT4
3 10.52 VEGFC FLT4
4
Show member pathways
10.16 VEGFC FLT4

GO Terms for Lymphedema

Biological processes related to Lymphedema according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.89 VEGFC SOX18 GATA2 FOXC2
2 angiogenesis GO:0001525 9.72 VEGFC SOX18 FLT4
3 positive regulation of angiogenesis GO:0045766 9.65 VEGFC GATA2 CCBE1
4 positive regulation of endothelial cell proliferation GO:0001938 9.6 VEGFC FLT4
5 blood vessel development GO:0001568 9.58 SOX18 FOXC2
6 collagen fibril organization GO:0030199 9.58 FOXC2 ADAMTS3
7 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.57 GATA2 FOXC2
8 cell maturation GO:0048469 9.56 SOX18 GATA2
9 respiratory gaseous exchange GO:0007585 9.54 FLT4 CCBE1
10 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.54 VEGFC FOXC2 FLT4
11 positive regulation of vascular endothelial growth factor production GO:0010575 9.52 FLT4 CCBE1
12 vasculature development GO:0001944 9.51 SOX18 FLT4
13 positive regulation of endothelial cell migration GO:0010595 9.5 FOXC2 FLT4 CCBE1
14 embryonic heart tube development GO:0035050 9.49 SOX18 FOXC2
15 vascular endothelial growth factor signaling pathway GO:0038084 9.46 VEGFC FLT4
16 respiratory system process GO:0003016 9.43 FLT4 CCBE1
17 positive regulation of vascular endothelial growth factor signaling pathway GO:1900748 9.4 CCBE1 ADAMTS3
18 sprouting angiogenesis GO:0002040 9.33 VEGFC FLT4 CCBE1
19 positive regulation of lymphangiogenesis GO:1901492 9.26 VEGFC CCBE1
20 lymph vessel development GO:0001945 9.26 SOX18 FOXC2 FLT4 CCBE1
21 lymphangiogenesis GO:0001946 9.02 SOX18 PTPN14 FOXC2 FLT4 CCBE1

Sources for Lymphedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....